<DOC>
	<DOCNO>NCT00709878</DOCNO>
	<brief_summary>The purpose study characterize microscopic finding skin rash associate use chemotherapeutic anticancer agent know epidermal growth factor inhibitor ( EGFRIs ) .</brief_summary>
	<brief_title>Histological Characterization Differentiation Rash From Other Epidermal Growth Factor Receptor ( EGFR ) Inhibitors</brief_title>
	<detailed_description>Epidermal growth factor ( EGF ) receptor , EGFR , know key driver cellular proliferation survival . Malignant tumor result uncontrolled cell proliferation . The use drug target EGF receptor offer patient non-small cell lung cancer , pancreatic cancer , head neck cancer , colorectal cancer additional target anti-cancer therapy addition chemotherapeutic regimen . As result increase use EGFR inhibitor , adverse event emerge involve skin , hair , nails eye . While EGFR inhibitor block signal transduction interfere cellular proliferation survival cancerous cell , also affect normal EGF function skin ( papulopustular rash ) , hair , nail . In study , seek histologically characterize papulopustular rash patient treat lapatinib compare finding associate three EGFRIs , cetuximab , erlotinib panitumumab .</detailed_description>
	<mesh_term>Exanthema</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Patients treat lapatinib developed skin toxicity biopsied . Patients treat erlotinib , cetuximab , panitumumab biopsied skin rash . Patients fit criterion .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>skin rash , lapatinib , cetuximab , erlotinib , panitumumab</keyword>
</DOC>